Elevated expression of FGF-2 does not cause prostate cancer progression in LNCaP cells

Prostate

Volumn 40, Issue 1, 1999, Pages 1-13

  Russell, Pamela J ^a,b   Bennett, S ^a,b   Joshua, A ^a,b   Yu, Y ^a   Downing, S R ^a,b   Hill, M A ^b   Kingsley, E A ^a,b   Mason, R S ^c   Berry, J ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Androgen independent prostate cancer; Growth factors; Xenografts

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR;

ARTICLE; BONE CELL; CANCER GROWTH; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; DISEASE COURSE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; XENOGRAFT;

ANIMALS; CELL DIVISION; DIHYDROTESTOSTERONE; DISEASE PROGRESSION; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TESTOSTERONE; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033564533     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990615)40:1<1::AID-PROS1>3.0.CO;2-K     Document Type: Article

References (63)

1. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994;44:7-26.
2. Lubahn DB, Joseph DR, Sar M, Tan J, Higgs HN, Larson RE, French FS, Wilson EM. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 1988;2:1265-1275.
3. Cunha GR, Alarid ET, Turner T, Donjacour AA, Boufin EL, Foster BA. Normal and abnormal development of the male urogenital tract - role of androgens, mesenchymal-epithelial interactions and growth factors. J Androl 1992;13:465-475.
4. Lee C. Role of androgen in prostate growth and regression: stromal-epithelial interaction. Prostate [Suppl] 1996;6:52-56.
5. Chung LWK, Gleave ME, Hsieh J, Hong SJ, Zhau HE. Reciprocal mesenchymal-epithelial interaction affecting prostate tumor growth and hormonal responsiveness. Cancer Surv 1991;11:91-119.
6. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 1991;67:3057-3064.
7. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C. Nuclear localization of androgen receptor in heterogeneous samples of normal prostate, hyperplastic and neoplastic human prostate. J Urol 1992;147:798-803.
8. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986;i:60-63.
9. Gleave ME, Hsieh J-T. Animal models in prostate cancer. In: Raghavan D, Scher HI, Leibel SA, Lange PH, editors. Principles and practice of genitourinary oncology. Philadelphia: Lippincott-Raven Publishers; 1997. p 367-378.
10. Bentel JM, Tilley WD. Androgen receptors in prostate cancer. J Endocrinol 1996;151:1-11.
11. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Kerr HN, Back SP. Mutations of the androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-1398.
12. Gaddipati JP, Mcleod DG, Heidenbery HB, Seterhen IA, Finger MJ, Moul JW. Frequent detection of codon 877 mutations in the androgen receptor gene in advanced prostate cancer. Cancer Res 1994;54:2861-2864.
13. Veldscholte J, Voorhorst-Ogink MM, Bolt-de Vries J, van Rooji HCJ, Trapman J, Mulder E. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochim Biophys Acta 1990;1052:187-194.
14. Schoenberg MP, Hakimi JM, Wang S, Bova GS, Epstein JI, Fishbeck KH, Isaacs WB, Walsh PC, Barrack ER. Microsatellite mutation (CAG 24-18) in the androgen receptor in human prostate cancer. Biochem Biophys Res Commun 1994;198:74-80.
15. Rundlett SE, Wu XP, Miesfeld RL. Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. Mol Endocrinol 1990;4:7211-7215.
16. Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991;226:510-518.
17. Gerber H-P, Seipei K, Grorgiev O, Hofferer M, Hug M, Rusconi S, Schaffner W. Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science 1994;263: 808-811.
18. Koivisto P, Hyytinen E, Palmberg C, Tammela T, Viskakorpi T, Isola J, Kallioniemi OP. Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am J Pathol 1995;147:1608-1614.
19. Visakorpi T, Hyytinen E, Holivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;4:401-406.
20. Isaacs JT, Cussenot O, Jankevicius F, Klocker H, Kubota Y, Morgia G, Rennie P, Schmitz-Drager BJ. Growth regulation of normal and malignant prostatic cells. In: Murphy G, Griffiths K, Denis L, Khoury S, Chatelain C, Cockett AT, editors. Proceedings of First International Consultation on Prostate Cancer 1996 June 20-22; Monaco. Scientific Communication International Ltd.; 1997. p 31-81.
21. Sherwood ER, Fong C-J, Lee C, Kozlowsski JM. Basic fibroblast growth factor: a potential mediator of stromal growth in the human prostate. Endocrinology 1992;130:2955-2963.
22. Mansson PE, Adams P, Kan M, McKeehan WL. Heparin-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors. Cancer Res 1989;49:2485-2494.
23. Yan G, Fukabori Y, McBride G, Nilolaropolous S, McKeehan WL. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993;13:4513-4522.
24. Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco MA. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 1997;15:3059-3065.
25. Geller J, Sionit LR, Baird A, Kohls M, Connors KM, Hoffman RM. In vivo and in vitro effects of androgen on fibroblast growth factor-2 concentration in the human prostate. Prostate 1994;25:206-209.
26. Sato N, Watabe Y, Suzuki H, Shimazaki J. Progression of androgen-sensitive mouse tumor (Shionogi carcinoma 115) to androgen-insensitive tumor after long-term removal of testosterone. Jpn J Cancer Res 1993;84:1300-1308.
27. Zuck B, Goepfert C, Nedlin-Chittka A, Sohrt K, Voight KD, Knabbe C. Regulation of fibroblast growth factor-like proteins in the androgen-responsive human prostate cell line, LNCaP. J Steroid Biochem Mol Biol 1992;41:659-663.
28. Nakamoto T, Chang CS, Li AK, Chodak GW. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 1992; 52:571-577.
29. Pretlow T, Delmoro C, Dilley O, Spadafora C, Pretlow T. Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res 1991;51:3814-3817.
30. Kern FG, McLeskey SW, Zhang L, Kurebayashi J, Liu Y, Ding IY, Kharbanda S, Chen D, Miller D, Cullen K, Paik S, Dickson RB. Transfected MCF-7 cells as a model for breast-cancer progression. Breast Cancer Res Treat 1994;31:153-165.
31. Folkman J. What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
32. Gleave ME, Hsieh JT, von Eschenbach AC, Chung LWK. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 1992; 147:1151-1159.
33. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
34. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rate adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 1976;73:2424-2428.
35. Damon DH, D'Amore PA, Wagner JA. Nerve growth factor and fibroblast growth factor regulate neurite outgrowth and gene expression in PC12 cells via both protein kinase C- and cAMP-independent mechanisms. J Cell Biol 1990;110:1333-1339.
36. Buttke TM, McCubrey JA, Owen TC. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J Immunol Methods 1993;157:233-240.
37. Zhao X, van Steenbrugge GJ, Schroder FH. Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor. Urol Res 1992;20: 193-197.
38. Steiner MS, Barrack ER. Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 1992;6:15-25.
39. Jarrard DF, Blitz BF, Smith RC, Patai BL, Rukstalis DB. Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. Prostate 1994;24:46-53.
40. Degeorges A, Tatoud R, Fauvel-Lafeve F, Podgorniak MP, Millot G, de Cremoux P, Calvo F. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor forLN-CaP prostate cancer cells, identified as interleukin-6. Int J Cancer 1996;68:207-214.
41. Reyes-Moreno C, Frenette G, Boulanger J, Lavergne E, Govindan MV, Koutsilieris M. Mediation of glucocorticoid receptor function by transforming growth factor beta 1 expression in human PC-3 prostate cancer cells. Prostate 1995;26:260-269.
42. Iwamura M, Sluss PM, Casamento JB, Cockett ATK. Insulin-like growth factor 1: action and receptor characteristics in human prostatic cancer cell lines. Prostate 1993;22:243-252.
43. Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL. Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol Endocrinol 1992;6:2123-2128.
44. Luo D, Lin Y, Liu X, Qin Z, Zhao C, Zhang Y, Yu Z. Effect of prostatic growth factor, basic fibroblast growth factor, epidermal growth factor, and steroids on the proliferation of human fetal prostatic fibroblasts. Prostate 1996;28:352-358.
45. Russell PJ, Raghavan D, Gregory P, Philips J, Wills EJ, Jelbart M, Wass J, Zbroja R, Vincent PC. Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Res 1986;46:2035-2040.
46. Slater M, Patava J, Kingham K, Mason RS. Modulation of growth factor incorporation into ECM of human osteoblast-like cells in vitro by 17b-estradiol. Am J Physiol 1994;267:9901-001.
47. Bennett S, Joshua A, Russell PJ. Reliable method of isolating transfected clones from the LNCaP human prostatic cell line. Biotechniques 1997;23:66-70.
48. Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998;44:705-723.
49. Fowler JE, Tau LK, Ghosh L. Epidermal growth factor and prostatic carcinoma: an immunohistochemical study. J Urol 1988; 139:857-861.
50. Yang Y, Chisholm GD, Habib FK. Epidermal growth factor and transforming growth factor alpha concentrations in BPH and cancer of the prostate: their relationship with tissue androgen levels. Br J Cancer 1993;67:152-155.
51. Harper ME, Goddard L, Glynnejones E, Wilson DW, Price-Thomas M, Peeling WB, Griffiths K. An immunochemical analysis of TGF-alpha expression in benign and malignant prostate. Prostate 1993;23:9-23.
52. Glynnejones E, Goddard L, Harper ME. Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Hum Pathol 1996;27:688-694.
53. Cohen DW, Simak R, Fair WR, Melded J, Scher HI, Cordon-Cardo C. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostatic tissue. J Urol 1994;152:2120-2124.
54. Chung LW, Li W, Gleave ME, Sikes RA, Zhau HE, Bandyk MG, Logothetis CJ, Rubin JS, von Eschenbach AC. Human prostate cancer model: roles of growth factors and extracellular matrices. J Cell Biochem [Suppl] 1992;16:99-105.
55. MacDonald A, Habib FK. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br J Cancer 1992;65:177-182.
56. Fudge K, Wang CY, Stearns ME. Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod Pathol 1994;7:549-554.
57. Quarto N, Talarico D, Sommer A, Florkiewicz R, Basilico C, Rifkin DB. Transformation by basic fibroblast growth factor requires high levels of expression: comparison with transformation by hst/K-fgf. Oncogene Res 1989;5:101-110.
58. Abraham JA, Whang JL, Tumolo A, Mergia A, Freidman J, Gospodarowicz D, Fiddes JC. Human basic fibroblast growth factor: nucleotide sequence and genomic organisation. EMBO J 1986;5:2523-2528.
59. Werner S, Duan DS, de Vries C, Peters KG, Johnson DE, Williams LT. Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol 1992;12:82-88.
60. Yayon A, Klagsbrun M. Autocrine regulation of cell growth and transformation by basic fibroblast growth factor. Cancer Metastasis Rev 1990;9:191-202.
61. Maret A, Galy B, Arnaud E, Bayard F, Prats H. Inhibition of fibroblast growth factor 2 expression by antisense RNA induced a loss of the transformed phenotype in a human hepatoma cell line. Cancer Res 1995;55:5075-5079.
62. Miyake H, Hara I, Yoshimura K, Eto H, Arakawa S, Wada S, Chilhara K, Kamidono S. Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential. Cancer Res 1996;56:2440-2445.
63. Matuo Y, Nishi N, Takasuka H, Masuda Y, Nishikawa K, Isaacs JT, Adams PS, McKeehan WL, Sato GH. Production and significance of TCP-beta in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma. Biochem Biophys Res Commun 1990;166:840-847.